Torrent Pharmaceuticals' Q2 FY 2025-26 Quarterly Results
- 16 Nov 2025
Result Summary
- Torrent Pharmaceuticals Ltd reported a 4.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 14.0%.
- Its expenses for the quarter were up by 2.8% QoQ and 11.7% YoY.
- The net profit increased 7.8% QoQ and increased 30.5% YoY.
- The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 17.45 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
| (₹ crores) | Q2FY26 | Q1FY26 | Q2FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3275.00 | 3141.00 | 2873.00 | 4.3% | 14.0% |
Total Expenses | 2471.00 | 2403.00 | 2212.00 | 2.8% | 11.7% |
Profit Before Tax | 791.00 | 738.00 | 661.00 | 7.2% | 19.7% |
Tax | 200.00 | 190.00 | 208.00 | 5.3% | -3.8% |
Profit After Tax | 591.00 | 548.00 | 453.00 | 7.8% | 30.5% |
Earnings Per Share | 17.45 | 16.19 | 13.37 | 7.8% | 30.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Torrent Pharmaceuticals Ltd is a leading pharmaceutical company based in India, known for its significant contributions to the healthcare industry. The company focuses on the development, production, and distribution of a wide range of pharmaceutical products. It is involved in various therapeutic areas including cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, and pain management segments. Torrent Pharmaceuticals has a strong presence in both domestic and international markets, offering a diverse portfolio of branded and generic medications. Recent developments include expansion in its global operations and investments in research and development to innovate new therapeutic solutions.
Revenue
During the second quarter of the fiscal year 2026 (Q2FY26), Torrent Pharmaceuticals Ltd reported a total income of ₹3275.00 crores, marking an increase from both the previous quarter (Q1FY26) and the same quarter of the previous fiscal year (Q2FY25). The quarter-over-quarter (QoQ) growth in total income was 4.3%, while the year-over-year (YoY) growth was 14.0%. This upward trend in revenue indicates a continuing growth trajectory for the company during the observed period. The consistent increase in revenue over these periods reflects the company's ability to enhance its sales and revenue streams.
Profitability
In terms of profitability, Torrent Pharmaceuticals Ltd reported a profit before tax of ₹791.00 crores in Q2FY26, which signifies a QoQ increase of 7.2% and a YoY growth of 19.7%. After accounting for taxes, the company recorded a profit after tax of ₹591.00 crores, representing a 7.8% increase QoQ and a 30.5% increase YoY. The earnings per share (EPS) for Q2FY26 was ₹17.45, up from ₹16.19 in Q1FY26 and ₹13.37 in Q2FY25, reflecting the same percentage growth as profit after tax. These figures demonstrate a robust improvement in the company's profitability metrics across both quarterly and annual comparisons.
Operating Metrics
Torrent Pharmaceuticals Ltd's operating expenses totaled ₹2471.00 crores in Q2FY26, up by 2.8% QoQ and 11.7% YoY. Despite the rise in expenses, the company managed to enhance its profitability, as indicated by the higher growth rates in profit before and after tax compared to the increase in expenses. The effective tax rate for Q2FY26 was approximately 25.3%, slightly lower than the same period last year. The data suggests efficient management of operational costs relative to revenue growth, contributing to the enhanced profitability outcomes observed in this quarter.
FAQs
When was Torrent Pharmaceuticals Ltd Q2 FY 2025-26 result announced?
Torrent Pharmaceuticals Ltd announced its Q2 FY 2025-26 results on 16 November, 2025.
What are Torrent Pharmaceuticals Ltd quarterly results?
Torrent Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Torrent Pharmaceuticals Ltd Q2 FY 2025-26 results?
Key highlights of Torrent Pharmaceuticals Ltd Q2 FY 2025-26 results include:
- Revenue: ₹3275.00 crore
- Net Profit: ₹591.00 crore
- EBITDA: ₹1043.00 crore
- Year-over-Year Growth: 14.0%
- Quarter-over-Quarter Growth: 4.3%
How did Torrent Pharmaceuticals Ltd net profit perform in this quarter?
Torrent Pharmaceuticals Ltd reported a net profit of ₹591.00 crore in Q2 FY 2025-26, reflecting a 30.5% year-over-year growth.
What was Torrent Pharmaceuticals Ltd revenue in Q2 FY 2025-26?
Torrent Pharmaceuticals Ltd posted a revenue of ₹3275.00 crore in Q2 FY 2025-26.